Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 


Doctors Lounge - Pharmacy Blogs

Chemotherapy and cardiac toxicity - the lesser of two evils

Author: John Kenyon, CNA
Submitted: September 15, 2010. Updated: October 07, 2010.
Category: Cardiology | Family Medicine | Hematology | Internal Medicine | Medical Students | Preventive Medicine | Oncology | Pathology | Pharmacy | Radiology | Research

One of the most dreaded side effects of certain chemotherapy agents is their effect on the heart. The paradox comes from the fact that these drugs, while only a handful, are among the few chemotherapy agents with a substantial survival benefit. In… Read more... (Comments: 0)


Massive Recall of Tylenol in USA, UAE and Fiji

Author: Tamer M. Fouad, M.D.
Submitted: January 16, 2010. Updated: January 16, 2010.
Category: Family Medicine | Internal Medicine | Neurology | Orthopedics | Pharmacy | Rheumatology | Surgery | Anesthesiology & Pain

Johnson and Johnson is extending the voluntary recall of certain lots of OTC products in the Americas, the United Arab Emirates (UAE), and Fiji. This includes Tylenol, Motrin and St. Joseph’s aspirin (FULL RECALLED PRODUCT LIST BELOW). The company… Read more... (Comments: 0)


Rituximab drastically reduces efficacy of H1N1 vaccine in rheumatoid patients

Author: Tamer M. Fouad, M.D.
Submitted: January 07, 2010. Updated: January 07, 2010.
Category: Family Medicine | Infections | Internal Medicine | Immunology | Preventive Medicine | Oncology | Pharmacy | Pulmonology | Rheumatology

Rheumatoid arthritis (RA) patients are partially protected by the influenza vaccine 6-10 months after treatment with rituximab. Researchers determined that while the flu vaccine is safe, it is ineffective for RA patients in the first 6 months following… Read more... (Comments: 0)


Four drug adjuvant chemotherapy with capecitabine improves breast cancer survival

Author: Tamer M. Fouad, M.D.
Submitted: January 03, 2010. Updated: January 03, 2010.
Category: Oncology | Pharmacy

Joensuu et al published an interesting study1 in which they randomized 1500 women with axillary node-positive or high-risk node-negative breast cancer, in an open-label trial, to either three cycles of capecitabine and docetaxel followed… Read more... (Comments: 0)


advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.